<DOC>
	<DOC>NCT00665639</DOC>
	<brief_summary>To determine the efficacy and safety of daily doses of IV micafungin versus IV caspofungin for the treatment of esophageal candidiasis</brief_summary>
	<brief_title>Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis, Oral</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>Esophageal candidiasis confirmed by endoscopy Negative pregnancy test for female patients of childbearing potential Pregnant or nursing female patient Evidence of liver disease Another active opportunistic fungal infection and/or receiving acute systemic therapy for an opportunistic fungal infection Concomitant esophagitis caused by herpes simplex virus or cytomegalovirus Received an oral or topical antifungal agent within 48 hours or a systemic antifungal agent within 72 hours of first dose of study drug Known to be nonresponsive to therapy in any prior systemic antifungal clinical trail Experienced &gt; 2 episodes of esophageal candidiasis requiring systemic antifungal therapy History of anaphylaxis attributed to echinocandin class of antifungals</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>Esophageal Candidiasis</keyword>
	<keyword>caspofungin</keyword>
</DOC>